Abstract
Pituitary tumors constitute 10–15% of all primary intracranial tumors and are categorized into two broad classifications: pituitary adenomas, which are benign and do not metastasize to other parts of the body, and pituitary carcinomas, which are malignant and may spread both within the central nervous system (CNS) and outside of it Sivakumar et al. (Neurosurg Focus 31(6):E18, 2011). Most pituitary tumors are benign adenomas affecting the tissues of the anterior pituitary, with pituitary carcinomas and tumors of the posterior pituitary being extremely rare. Pituitary adenomas may be classified as microadenomas, defined as <10 mm in its greatest diameter, or (macro)adenomas, which are ≥10 mm in diameter. The most clinically meaningful designation for an adenoma is its functional status; pituitary adenomas may either be classified as hyperfunctioning adenomas that secrete excess amounts of the hormone typically secreted by the tissue comprising the adenoma or nonfunctioning adenomas, indicating that the adenoma simply occupies anatomic space but does not produce excess hormone secretion.
In this chapter, we will describe the epidemiology, etiology, prevention, detection, anatomy, pathology, workup, and treatment of pituitary tumors. A special emphasis will be placed on radiation therapy as primary treatment, detailing the various radiation techniques that may be utilized. Due to the numerous tissues that constitute the pituitary gland and their location, the manifestations and treatment of these tumors are varied and complex; consequently, optimal management of these tumors requires a treatment team of members of different specialties, including primary care physicians, endocrinologists, radiation oncologists, neurosurgeons, neuroradiologists, otolaryngologists, and neuropathologists.
References
Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(8):843–9. https://doi.org/10.1136/jnnp-2012-303194.
Arauz R, Rodriguez M. RT-02Comparison of 3DCRT, IMRT and VMAT for post surgery radiotherapy for pituitary macroadenomas. Neuro-Oncol. 2014;16(Suppl 5):v188. https://doi.org/10.1093/neuonc/nou270.2.
Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass J a. H. Nelson’s syndrome. Eur J Endocrinol 2010;163(4):495–507. https://doi.org/10.1530/EJE-10-0466.
Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau J-L. 2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013;2(2):76–82. https://doi.org/10.1159/000351007.
Bhandare N, Jackson A, Eisbruch A, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S50–7. https://doi.org/10.1016/j.ijrobp.2009.04.096.
Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol. 1993;38(6):571–8.
Cavagnini F, Pecori Giraldi F. Epidemiology and follow-up of cushing’s disease. Ann Endocrinol. 2001;62(2):168–72.
Chanson P, Brochier S. Non-functioning pituitary adenomas. J Endocrinol Investig. 2005;28(11 Suppl International):93–9.
Chaudhary V, Bano S. Imaging of the pituitary: recent advances. Indian J Endocrinol Metab. 2011;15(Suppl 3):S216–23. https://doi.org/10.4103/2230-8210.84871.
Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in cushing’s disease. N Engl J Med. 2012;366(10):914–24. https://doi.org/10.1056/NEJMoa1105743.
Day PF, Loto MG, Glerean M, Picasso MFR, Lovazzano S, Giunta DH. Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a health management organization in Buenos Aires, Argentina. Arch Endocrinol Metab. 2016;60(6):554–61. https://doi.org/10.1590/2359-3997000000195.
Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for cushing’s disease. J Clin Endocrinol Metab. 1997;82(10):3196–202. https://doi.org/10.1210/jcem.82.10.4290.
Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab. 1979;48(6):931–40. https://doi.org/10.1210/jcem-48-6-931.
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.
Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;93(3):597–601. https://doi.org/10.1016/j.radonc.2009.09.011.
Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in cushing’s disease. N Engl J Med. 1997;336(3):172–7. https://doi.org/10.1056/NEJM199701163360303.
Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–9. https://doi.org/10.1002/cncr.20412.
Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3013–8. https://doi.org/10.1210/jcem.87.7.8665.
Gil-Cárdenas A, Herrera MF, Díaz-Polanco A, Rios JM, Pantoja JP. Nelson’s syndrome after bilateral adrenalectomy for cushing’s disease. Surgery. 2007;141(2):147–151–152. https://doi.org/10.1016/j.surg.2006.12.003.
Guckenberger M, Baier K, Guenther I, et al. Reliability of the bony anatomy in image-guided stereotactic radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys. 2007;69(1):294–301. https://doi.org/10.1016/j.ijrobp.2007.05.030.
Heaney AP. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(12):3649–60. https://doi.org/10.1210/jc.2011-2031.
Iwata H, Sato K, Tatewaki K, et al. Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-Oncol. 2011;13(8):916–22. https://doi.org/10.1093/neuonc/nor055.
Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML. Gamma knife surgery for cushing’s disease. J Neurosurg. 2007;106(6):980–7. https://doi.org/10.3171/jns.2007.106.6.980.
Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JAH. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006;91(4):1239–45. https://doi.org/10.1210/jc.2005-1616.
Jennings AS, Liddle GW, Orth DN. Results of treating childhood cushing’s disease with pituitary irradiation. N Engl J Med. 1977;297(18):957–62. https://doi.org/10.1056/NEJM197711032971801.
John HS, Sam TC, Erin SM, Robert JW. Pituitary tumors and craniopharyngiomas. In clinical radiation oncology (Fourth Edition), edited by Leonard L. Gunderson and Joel E. Tepper, Elsevier, Philadelphia, 2016;502--520.e4, https://doi.org/10.1016/B978-0-323-24098-7.00029–0
Kennedy WR, Dagan R, Rotondo RL, Louis D, Morris CG, Indelicato DJ. Proton therapy for pituitary adenoma. Int J Radiat Oncol • Biol • Phys. 2014;90(1):S299. https://doi.org/10.1016/j.ijrobp.2014.05.1006.
Klibanski A. Prolactinomas. 2010. http://www.nejm.org/doi/full/10.1056/NEJMcp0912025. Published 8 Apr 2010. Accessed 31 May 2017
Kreutzer J, Buslei R, Wallaschofski H, et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008;158(1):11–8. https://doi.org/10.1530/EJE-07-0248.
Lee C-C, Vance ML, Xu Z, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab. 2014;99(4):1273–81. https://doi.org/10.1210/jc.2013-3743.
Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518–20. https://doi.org/10.1016/S1470-2045(06)70728-8.
Liscák R, Vladyka V, Marek J, Simonová G, Vymazal J. Gamma knife radiosurgery for endocrine-inactive pituitary adenomas. Acta Neurochir. 2007;149(10):999–1006. discussion 1006. https://doi.org/10.1007/s00701-007-1253-7.
Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7):1992–2003. https://doi.org/10.1210/jc.2011-0251.
Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary radiotherapy for cushing’s disease. Neuroendocrinology. 2010;92(Suppl 1):107–10. https://doi.org/10.1159/000314299.
Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168–75. https://doi.org/10.4103/0974-1208.121400.
Malchiodi E, Profka E, Ferrante E, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab. 2014;99(6):2069–76. https://doi.org/10.1210/jc.2013-4376.
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–17. https://doi.org/10.1210/jc.2008-2421.
Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg. 2006;104(6):876–83. https://doi.org/10.3171/jns.2006.104.6.876.
Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R. Long-term follow-up results of postoperative radiation therapy for cushing’s disease. J Neuro-Oncol. 2007;84(1):79–84. https://doi.org/10.1007/s11060-007-9344-0.
Minniti G, Scaringi C, Enrici RM. Radiation techniques for acromegaly. Radiat Oncol Lond Engl. 2011;6:167. https://doi.org/10.1186/1748-717X-6-167.
Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985;60(4):698–705. https://doi.org/10.1210/jcem-60-4-698.
Nelson DH, Meakin JW, Dealy JBJ, Matson DD, Emerson KJ, Thorn GW. ACTH-producing tumor of the pituitary gland. N Engl J Med. 1958;259(4):161–4. https://doi.org/10.1056/NEJM195807242590403.
Ouyang T, Rothfus WE, Ng JM, Challinor SM. Imaging of the pituitary. Radiol Clin N Am. 2011;49(3):549–571. vii. https://doi.org/10.1016/j.rcl.2011.02.012.
Park K-J, Kano H, Parry PV, et al. Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery. 2011;69(6):1188–99. https://doi.org/10.1227/NEU.0b013e318222afed.
Petersenn S, Beckers A, Ferone D, et al. Therapy of endocrine disease: outcomes in patients with cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol. 2015;172(6):R227–39. https://doi.org/10.1530/EJE-14-0883.
Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys. 2008;70(5):1325–9. https://doi.org/10.1016/j.ijrobp.2007.08.018.
Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary. 2012;15(1):71–83. https://doi.org/10.1007/s11102-011-0347-7.
Rogers A, Karavitaki N, Wass JAH. Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ. 2014;349:g5390.
Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery. 2005;56(5):1066–74.
Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol. 2015;114(2):230–8. https://doi.org/10.1016/j.radonc.2015.01.016.
Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML. Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114(2):303–9. https://doi.org/10.3171/2010.5.JNS091635.
Sheehan JP, Starke RM, Mathieu D, et al. Gamma knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446–56. https://doi.org/10.3171/2013.3.JNS12766.
Sivakumar W, Chamoun R, Nguyen V, Couldwell WT. Incidental pituitary adenomas. Neurosurg Focus. 2011;31(6):E18. https://doi.org/10.3171/2011.9.FOCUS11217.
Starke RM, Williams BJ, Jane JA, Sheehan JP. Gamma knife surgery for patients with nonfunctioning pituitary macroadenomas: predictors of tumor control, neurological deficits, and hypopituitarism. J Neurosurg. 2012;117(1):129–35. https://doi.org/10.3171/2012.4.JNS112250.
Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone–receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7. https://doi.org/10.1056/NEJM200004203421604.
van den Bergh ACM, van den Berg G, Schoorl MA, et al. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys. 2007;67(3):863–9. https://doi.org/10.1016/j.ijrobp.2006.09.049.
Voges J, Kocher M, Runge M, et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer. 2006;107(6):1355–64. https://doi.org/10.1002/cncr.22128.
Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90(3):532–9. https://doi.org/10.1016/j.ijrobp.2014.06.068.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this entry
Cite this entry
Bajaj, A., Solanki, A.A., Miller, C., Altoos, B., Giordano, F.A., Shih, H.A. (2018). Radiation Therapy in Tumors of the Pituitary Gland. In: Wenz, F. (eds) Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-52619-5_6-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52619-5_6-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52619-5
Online ISBN: 978-3-319-52619-5
eBook Packages: Springer Reference MedicineReference Module Medicine